Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 59

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 59
---
 officer, our chief financial officer (who also serves as our chief strategy officer) and our other three most highly compensated executive officers who were serving as such at the end of our fiscal year 2024 (collectively referred to as our "named executive officers"). Those named executive officers were:

• Gene G. Kinney, Ph.D., our President and Chief Executive Officer;

• Tran B. Nguyen, our Chief Strategy Officer and Chief Financial Officer;

• Brandon S. Smith, our Chief Operating Officer;

• Carol D. Karp, our Chief Regulatory Officer; and

• Wagner M. Zago, Ph.D., our Chief Scientific Officer.

| Executive Summary: Fiscal Year 2024 Company Performance and Key Pay Decisions |

2024 Performance Highlights. We are a late-stage clinical company with a robust pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Our executive compensation programs are designed to reward superior performance and provide consequences for under-performance. We believe that compensation of our named executive officers for fiscal year 2024 was aligned with the Company’s performance during 2024 and its go-forward strategy. Highlights of that performance include:

• We Made Significant Advances in our Neurodegenerative Diseases Portfolio .

◦ PRX012, a wholly-owned potential best-in-class, next-generation subcutaneous antibody for the treatment of Alzheimer’s disease (AD) that targets a key epitope at the N-terminus of amyloid beta (Aβ) with high binding potency. In 2024, Prothena continued enrollment in our ongoing ASCENT clinical trials (reaching approximately 260 patients) and presented posters at the Alzheimer’s Association International Conference (AAIC) and the Clinical Trials on Alzheimer’s Disease conference (CTAD) highlighting the clinical trial design of the Phase 1 ASCENT clinical trials.

◦ BMS-986446 (formerly PRX005), a potential best-in-class antibody for the treatment of AD that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of AD. BMS-986446 is part of the global neuroscience research and development collaboration with Bristol Myers Squibb (BMS). In 2024, BMS continued to enroll the ongoing Phase 2 TargetTau-1 clinical trial in approximately 475 patients with early Alzheimer’s disease and presented the design of the ongoing Phase 2 TargetTau-1 clinical trial in a poster